Clinical Trials Logo

Diabetic Retinopathy clinical trials

View clinical trials related to Diabetic Retinopathy.

Filter by:

NCT ID: NCT01023113 Recruiting - Clinical trials for Diabetic Retinopathy

To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation

Start date: September 2009
Phase: N/A
Study type: Interventional

Lacunae in Knowledge No study is available in literature regarding visual field impairment in proliferative diabetic retinopathy comparing conventional double frequency Nd:YAG panretinal photocoagulation with PASCAL panretinal photocoagulation AIMS & OBJECTIVE 1. To compare visual field impairment in conventional double frequency Nd: YAG panretinal photocoagulation with PASCAL panretinal photocoagulation. 2. To examine the effect of these modalities of laser on macular edema 60 eyes of proliferative diabetic retinopathy will undergo humphery visual field analysis,and optical coherence tomography before and after panretinal photocoagulation

NCT ID: NCT00908778 Recruiting - Clinical trials for Diabetic Retinopathy

A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects

Start date: October 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of Vitreosolve® in diabetic retinopathy patients.

NCT ID: NCT00855608 Recruiting - Clinical trials for Diabetic Retinopathy

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

ADA01
Start date: March 2009
Phase: Phase 1
Study type: Interventional

Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from the systemic circulation by the tight blood retinal barrier. Effective intraocular drug levels can be achieved with a much smaller amount of medication if injected intravitreally and this also results in minimal systemic exposure to the patient. Preliminary studies have shown that adalimumab may have a positive role in the management of uveitis in humans and can be an effective treatment intravitreally in animal models. No data has been published yet on intravitreal use of adalimumab in human subjects.

NCT ID: NCT00849537 Recruiting - Clinical trials for Diabetic Retinopathy

The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy

Start date: April 2008
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, regressed proliferative diabetic retinopathy, very severe, severe and moderate non-prolifrative diabetic retinopathy patients who were going to have a cataract surgery, underwent a complete eye examination, OCT, FAG and color photography 2 weeks prior to their operation. All patients divided in two: 1) control group (Phyco,PCIOL), 2) triamcinolone treatment group (Phaco with PCIOL+IVT). One month after surgery a complete eye examination will be done especially; IOP and endophthalmitis. A 6 month follow-up will be done for these two groups and diabetic retinopathy progression will be checked.

NCT ID: NCT00556244 Recruiting - Clinical trials for Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation

Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling

Start date: April 2007
Phase: Phase 1/Phase 2
Study type: Interventional

Internal limiting membrane peeling in diabetic vitrectomy will help prevent postoperative epiretinal membrane formation

NCT ID: NCT00524875 Recruiting - Clinical trials for Diabetic Retinopathy

Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients

Start date: January 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether bevacizumab 1-2 weeks before vitrectomy is effective in lowering the rate of early post-vitrectomy vitreous hemorrhage in diabetic patients.

NCT ID: NCT00516464 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Start date: August 2007
Phase: Phase 3
Study type: Interventional

Evaluation of ranibizumab on the ease and procedure and complication in proliferative diabetic retinopathy (PDR) requiring vitrectomy.

NCT ID: NCT00476918 Recruiting - Clinical trials for Diabetic Retinopathy

Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema

Start date: July 2006
Phase: Phase 1
Study type: Interventional

Efficacy duration of triamcinolone acetonide (steroid) for treatment of diabetic macular edema. Furthermore, dosage dependency of triamcinolone acetonide comparing a high dosage versus a low dosage.

NCT ID: NCT00403026 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Intravitreal Bevacizumab for Retinal Disorders

Start date: August 2006
Phase: N/A
Study type: Interventional

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.

NCT ID: NCT00370721 Recruiting - Clinical trials for Diabetic Retinopathy

Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

Start date: March 2006
Phase: Phase 3
Study type: Interventional

To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR